LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, announced it has initiated an operational, technical, and commercial evaluation process to support a potential integration of installment-based healthcare payment capabilities through Cashea, one of Venezuela’s leading buy-now-pay-later (BNPL) financial technology platforms.
The proposed initiative is designed to evaluate ways to reduce upfront financial barriers for patients seeking access to private healthcare services, consultations, diagnostics, wellness programs, and other eligible healthcare offerings through the LataMed AI ecosystem. Management believes that improving payment accessibility may support greater patient engagement, increased healthcare utilization, stronger platform adoption, and broader access to private healthcare services. By addressing affordability challenges, the Company believes it can further strengthen its position as a technology-enabled healthcare marketplace serving patients, providers, and healthcare partners throughout Latin America.
The Company expects that a potential Cashea-related payment integration, if successfully completed, could support LataMed AI’s broader strategy of combining artificial intelligence, telehealth infrastructure, care coordination tools, and digital payment accessibility to create a more scalable healthcare marketplace for patients and providers. This strategic move comes as LataMed AI continues to develop its telehealth and AI capabilities for emerging markets, with an initial regional focus on Latin America.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: “We believe financial accessibility is a critical component of healthcare delivery. Our objective is to evaluate solutions that may help patients obtain timely medical care while simultaneously expanding the reach and utility of our healthcare ecosystem. We believe initiatives such as this have the potential to strengthen patient acquisition, improve engagement, and support long-term platform growth.”
The Company has not entered into a definitive commercial agreement related to this initiative as of the date of this release. Completion of any integration remains subject to further commercial discussions, technical implementation requirements, regulatory review, and customary business conditions. LataMed AI intends to provide additional updates as material developments occur.
For additional information, please visit https://latamed.ai or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
